GPR21 recombinant proteins and antibodies

G-protein coupled receptor 21 (GPR21) is a receptor belonging to the G-protein coupled receptor (GPCR) family, predominantly expressed in the brain, gut, and adipose tissue. While the biological functions of GPR21 are not yet fully understood, research suggests that it plays a significant role in regulating energy metabolism, inflammatory responses, and brain function. GPR21 has gained attention as a potential therapeutic target for metabolic diseases, particularly obesity, diabetes, and other metabolic disorders. In recent years, its potential role in adipose metabolism and weight regulation has made it an important target in obesity research.

GPR21 is expressed in adipocytes and the liver, prompting researchers to explore its role in metabolic regulation. Initial studies have shown that GPR21 may be involved in the metabolism of fatty acids and the regulation of insulin sensitivity, playing a crucial role in the development of diabetes and obesity. As a result, drug development targeting GPR21 is becoming a focus, especially in the context of anti-obesity and anti-diabetic drugs. Some specific small molecule GPR21 agonists have been identified, which can activate the GPR21 receptor, regulate energy balance, and improve metabolic abnormalities such as those seen in diabetes.

In terms of drug development, several pharmaceutical companies have begun investing in GPR21-related drug research. Specific GPR21 agonists and inhibitors are entering preclinical stages, showing potential in treating diabetes, obesity, and other metabolic diseases. Biopharmaceutical companies are also developing multi-target combination therapies that include GPR21 alongside other drug targets such as adrenergic receptors and insulin receptors. Moreover, GPR21 is also being considered as a potential therapeutic target for neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases, with ongoing research and drug development in this area. With deeper research into GPR21’s receptor functions, more innovative GPR21-targeted drugs may emerge in the future. These drugs could not only provide new therapeutic options for metabolic diseases but also play an important role in treating neurodegenerative and other chronic diseases.

To assist in the development of GPR21-targeted drugs, DIMA BIOTECH can now provide full-length GPR21 recombinant membrane protein developed by its nanodisc membrane protein platform. GPR21 nanodisc is an optimal solution for screening small molecules targeting TLR9 with its natural structure. Furthermore, DIMA BIOTECH has also prepared a GPR21 single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days.